Cabazitaxel
Form: Injection
Strength: 60 mg/1.5 mL
Reference Brands: Jevtana®(US & EU)
Category: Oncology Cancer Care
Cabazitaxel, a next-generation taxane chemotherapy agent, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with docetaxel. Marketed under the brand Jevtana® in the US and EU, it is available as a 60 mg/1.5 mL injectable concentrate, requiring dilution before intravenous infusion. Cabazitaxel inhibits microtubule depolymerization, disrupting cancer cell mitosis. Manufactured under strict GMP standards, Cabazitaxel is a key product for B2B pharma partners focused on oncology and urology segments. It presents reliable commercial opportunities in highly regulated markets across Europe and North America.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details Get Enquiry
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details Get Enquiry
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details Get Enquiry
Ifosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details Get Enquiry